Abstract:Abstract Background: Clonal Hematopoiesis (CH) is a well established confounder in next-generation sequencing (NGS)-based liquid biopsy cancer diagnostics. Misclassification of CH variants as tumor variants can lead to false positive actionable variant detection, potentially resulting in incorrect interpretation of results and therapy selection. Moreover, CH variants may also interfere with quantitative variant monitoring leading to inaccurate assessment of treatment response. While filtering of CH variants is possible via matched sequencing of white blood cell and plasma DNA, emerging algorithmic approaches may enable a more resource-effective, time-sensitive approach with high precision. Methods: A random forest classifier was trained and validated on 1321 advanced, pan-solid tumor cancer samples (training n=660, validation n=661) sequenced using both the Tempus xF+ (liquid biopsy) and Tempus xT (solid tumor with matched buffy coat) NGS assays. Variants were labeled as CH or tumor-derived based on solid-tissue results in 39 genes that are known to be associated with CH (e.g., DNMT3A, TET2, TP53). The classifier was trained to classify SNV and indel variants detected via liquid biopsy as circulating-tumor or non-tumor (CH + germline) in origin. Features used by the classifier include the fragment size of reads overlapping each variant, prevalence in solid-tumor samples from the Tempus multimodal database, and variant allele fraction relative to estimated tumor fraction. Model classifications were validated against Tempus xT. Results: Our training set (n=660 liquid biopsy samples) included 680 pathogenic variants. 50% (n=342/680) were determined to be tumor-derived, while 50% (338/680) are likely due to CH. Our independent validation (n=661 samples) included 600 pathogenic variants. Model prediction accuracy on these validation set variants was 91.7%, with an ROC-AUC of 0.97. Sensitivity was 88.3% (n=257/291 true positives correctly labeled as non-tumor variants), specificity was 94.8% (n=293/309 true negatives correctly labeled as tumor variants), and precision was 94.1%. The model ranked “gene” as the most informative feature for variant classification, followed by measurements of fragment distribution and historical prevalence of individual variants within the Tempus Database. Conclusion: A novel classifier trained on multiple orthogonal bioinformatics features can reliably distinguish CH from tumor-derived variants using only liquid biopsy data with high accuracy, including high sensitivity and high specificity. Citation Format: Anne Sonnenschein, Maysun Hasan, Sandra Hui, Bob Tell, Halla Nimeiri, Jonathan Freaney, Kate Sasser, Wei Zhu, Christine Lo. Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2324.

A unique molecular identifier-based and clonal hematopoiesis-aware approach for accurate mutation calling in cell-free DNA assays.

Ultra-deep sequencing with unique molecular identifier(UMI) for detection of ctDNA by fragment profiling using machine learning.

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Detecting Ultralow Frequency Mutation in Circulating Cell‐Free DNA of Early‐Stage Nonsmall Cell Lung Cancer Patients with Unique Molecular Identifiers

An Ultra-Deep Next Generation Sequencing Method for Cfdna Detection in Nsclc Patients.

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

A CNV Computational Model for Clonal Origin Analysis of Synchronous Multifocal Hepatobiliary and Pancreatic Tumors.

Biological background of the genomic variations of cf-DNA in healthy individuals

CLAmp‐seq: A Novel Amplicon‐Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma Cfdna from Patients with NSCLC

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

High efficiency error suppression for accurate detection of low-frequency variants

Baseline mutation profiling of circulating cell-free DNA from healthy individuals to improve the detection accuracy of circulating tumor DNA in cancers.

A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection

Somatic Point Mutation Calling in Low Cellularity Tumors

Abstract P19: Comprehensive Benchmark of Somatic Mutation Callers on Cell-Free DNA Next-Generation Sequencing Data in Cancer Liquid Biopsy

Abstract 2324: Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy

Technical And Clinical Validation Of Somatic Cnv Detection From Circulating Tumor Dna.

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Abstract 3519: High-throughput Unbiased Microwell-Based Single-Cell CNV Detection Reveals Tumor Clonal Subtypes in Hepatocellular Carcinoma

Heterogeneous Mutation Pattern in Tumor Tissue and Circulating Tumor DNA Warrants Parallel NGS Panel Testing